Comment on: levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients
作者： JayaPrakash Sahoo , Sadishkumar Kamalanathan
DOI: 10.1007/S00296-014-3145-5
关键词: Internal medicine 、 Dipeptidyl peptidase 、 Endocrinology 、 Vildagliptin 、 Neuropeptide Y receptor 、 Rheumatology 、 Medicine 、 Vasoactive intestinal peptide 、 Sitagliptin 、 Dipeptidyl peptidase-4 、 Rheumatoid arthritis
摘要:
springer.com
sci-hub.se 参考文章(8)
Kazuki Yokota, Naoya Igaki, Sitagliptin (DPP-4 Inhibitor)-induced Rheumatoid Arthritis in Type 2 Diabetes Mellitus: A Case Report Internal Medicine. ,vol. 51, pp. 2041- 2044 ,(2012) , 10.2169/INTERNALMEDICINE.51.7592
Suncica Buljevic, Dijana Detel, Lara Baticic Pucar, Radovan Mihelic, Tomislav Madarevic, Branko Sestan, Jadranka Varljen, Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients Rheumatology International. ,vol. 33, pp. 2867- 2874 ,(2013) , 10.1007/S00296-013-2823-Z
Seoyoung C Kim, Sebastian Schneeweiss, Robert J Glynn, Michael Doherty, Allison B Goldfine, Daniel H Solomon, Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study Annals of the Rheumatic Diseases. ,vol. 74, pp. 1968- 1975 ,(2015) , 10.1136/ANNRHEUMDIS-2014-205216
Etienne Crickx, Ibrahim Marroun, Christine Veyrie, Christine Le Beller, Yoland Schoindre, Florence Bouilloud, Olivier Blétry, Jean-Emmanuel Kahn, DPP4 inhibitor-induced polyarthritis: a report of three cases Rheumatology International. ,vol. 34, pp. 291- 292 ,(2014) , 10.1007/S00296-013-2710-7
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, D. Matthews, Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 Diabetes Care. ,vol. 36, pp. 490- 490 ,(2013) , 10.2337/DC13-ER02
S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. ,vol. 55, pp. 1577- 1596 ,(2012) , 10.1007/S00125-012-2534-0
Daniel J Drucker, Michael A Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes The Lancet. ,vol. 368, pp. 1696- 1705 ,(2006) , 10.1016/S0140-6736(06)69705-5
S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews, Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. ,vol. 35, pp. 1364- 1379 ,(2012) , 10.2337/DC12-0413